Following are the relevant links to EUnetHTA Relative Effectiveness Assessments (REA) produced until August, 2021. Also accessible are the National Uptake & Case Studies overview, the Topic Identification, Selection & Prioritisation (TISP), and the resulting EUnetHTA Prioritisation Lists (EPL) for both Pharmaceutical Compounds and Other Technologies.
EUnetHTA Response to COVID-19
EUnetHTA JA3 Assessments both for Pharmaceutical Products and Medical Devices / Other Technologies might face delays in their publication due to the impact COVID-19 measures have on our authoring teams. Any delays will be communicated with the relevant partners as soon as we become aware of them.
Please read the full statement here.
EUnetHTA Joint Assessments (JA) are health technology assessments jointly produced by at least four EUnetHTA partners in different European countries. EUnetHTA processes, guidelines and the HTA Core Model® are used for the production of assessments that are subject to extensive review procedures in order to ensure high quality. JAs are centrally coordinated by the WP4 Co-Leads and comprise a broad stakeholder involvement, including the use of a EUnetHTA submission file in addition to a scoping (e-)meeting with industry.
EUnetHTA Collaborative Assessments (CA) are primarily produced in non-pharmaceutical technologies. They only differ from the EUnetHTA JAs with regard to coordination, i.e. the project management is performed in a decentralised manner by WP4 Co-Lead and WP4 Activity Centre Department Leads. In CAs, the use of submission file and scoping (e-)meeting with industry are optional. CAs should facilitate timelines that are aligned with national work programmes and should contribute to the sustainability of assessment production after 2020 due to decentralised coordination.Currently in Joint Action 3 (2016-2020), as of March 2016, EUnetHTA has finalised 20 joint assessments: 2 joint assessments during EUnetHTA Project (2006-2008), 3 joint assessments during EUnetHTA JA (2010-2012) and 15 joint assessments during EUnetHTA JA2 (2012-2015).
EUnetHTA Project Identifiers
All EUnetHTA assessments are given a unique identifier in order to allow easy identification of the assessments. Unique identifiers are assigned according to the start date of the assessments and need to be indicated on all assessment related documents.
EUnetHTA Joint Action 3
Project ID: [PT/OT][CA/JA] e.g. PTJA01
Please note that there is separate counting for pharmaceutical technologies and other technologies. However, collaborative assessments and joint assessments are counted together (e.g. OTCA6, OTCA7, OTJA8…).
EUnetHTA Joint Action 2
Pilot ID (rapid REA):WP5-SA-0 (Pharmaceutical Technologies: ranging from 1 until 6)WP5-SB-00 (Other Technologies: ranging from 11 until 16)Core HTAs: no unique identifier used
General abbreviations: OT-other technologies, PT-pharmaceutical technologies, CA-collaborative assessment, JA-joint assessment
This website was produced under the Third EU Health Programme through a service contract with the European Health and Digital Executive Agency (HaDEA) acting under the mandate from the European Commission. The information and views set out in this website are those of the author(s) and do not necessarily reflect the official opinion of the Commission/Executive Agency. The Commission/Executive Agency do not guarantee the accuracy of the data included in this website. Neither the Commission/Executive Agency nor any person acting on the Commission’s/Executive Agency’s behalf may be held responsible for the use which may be made of the information contained therein.
©2021 EUnetHTA All rights reserved.